NMS-P945

• Description:

  NMS-P945 is an ADC linker that can be used in the synthesis of antibody-drug conjugates (ADCs) . NMS-P945 is suitable for conjugation to mAbs with reproducible Drug Antibody Ratio (DAR) >3.5[1].

• UNSPSC:

  12352203

• Target:

  ADC Linker

• Type:

  ADC Related

• Related Pathways:

  Antibody-drug Conjugate/ADC Related

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/nms-p945.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(N1CCCCCC(N[C@@H](C(C)C)C(N[C@@H](CCCNC(N)=O)C(NC2=CC=C(COC(N(C)CCN(C)C(OC(C3=C4C(C)=CS3)=CC5=C4[C@H](CCl)CN5C(C6=CC(C=C(C=C7)OCCN8CCCC8)=C7N6)=O)=O)=O)C=C2)=O)=O)=O)C=CC1=O

• Molecular Formula:

  C61H76ClN11O12S

• Molecular Weight:

  1222.84

• References & Citations:

  [1]Valsasina B, Novel thienoduocarmycin-trastuzumab ADC demonstrates Strong Anti-tumor Efficacy with Favorable Safety Profile in Preclinical Studies. Mol Cancer Ther. 2023 Sep 19.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  ADC Related

• Clinical Information:

  No Development Reported

• CAS Number:

  [1466546-35-9]